{"id":133434,"date":"2022-08-24T07:31:05","date_gmt":"2022-08-24T11:31:05","guid":{"rendered":"https:\/\/44.250.171.167\/?p=133434"},"modified":"2022-10-06T04:45:36","modified_gmt":"2022-10-06T08:45:36","slug":"zydus-lifesciences-ltd-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-ltd-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Zydus Lifesciences Ltd Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Zydus Lifesciences Ltd Q1 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/R4mbpNYrIhE?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Zydus Lifesciences Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/ZYDUSLIFE\/\">ZYDUSLIFE<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Neha enquired about the drivers of strong growth in the US business QonQ and if it\u2019s sustainable. Sharvil Patel MD replied that there are no one-offs in the overall numbers. The sequential growth was due to volume share gain on the base portfolio and new launches. In future, Zydus is at a sustainable base which it expects to grow forward.<\/li>\n<\/ul>\n<ul>\n<li>Neha also enquired about the reasons for costs increase QonQ, especially employee costs. Nitin Parekh CFO replied that employee cost QonQ will not make sense as in April Zydus gives increments and incentives. So 8% impact is on account of increments and performance bonuses only, about 2.5% impact from actuarial gain and 1.5% due to new recruitments.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal enquired about the US business, if the improvement is due to volume improvement of good launches. Nitin Parekh CFO replied that the growth in the US is due to both volume growth and the new product growth also.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal also asked how does the company see the US business for the rest of year. Sharvil Patel MD replied that the company\u2019s base business is currently on track and believes the company can grow from that. \u00a0The company also has some important launches that are also phased in one or two quarters.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal asked about the outlook on margins. Sharvil Patel MD replied that the company believes it will be 20% plus margins and the company expects to sustain this margin for FY23.<\/li>\n<\/ul>\n<ul>\n<li>Vishal Manchanda enquired about Adalimumab biosimilar approval in Russia, the market size and competition. Sharvil Patel MD replied that the company will be the first or second generic. In terms of size, the data is not available.<\/li>\n<\/ul>\n<ul>\n<li>Sriman asked about an agreement with a Korean company and if it\u2019s getting any revenue from the tech being transferred to them. Sharvil Patel MD replied that the company is not yet getting any revenue and is in the phase of tech transfer that will be followed by a regulatory inspection in their facility.<\/li>\n<\/ul>\n<ul>\n<li>Sameer Baisiwala of Morgan Stanley asked about the US product pipeline for FY24. Sharvil Patel MD said it continues to expect 30-35 plus ANDAs in the US. ZYDUSLIFE believes it has a pipeline to do that and is buoyant about the next couple of years for US launches.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Zydus Lifesciences Ltd (ZYDUSLIFE) Q1 FY23 Earnings Concall Q&amp;A Highlights: Neha enquired about the drivers of strong growth in the US business QonQ and if it\u2019s sustainable. Sharvil Patel MD replied that there are no one-offs in the overall numbers. The sequential growth was due to volume share gain on the base [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Zydus Lifesciences Ltd Q1 FY23 Earnings Conference Call Insights #ZYDUSLIFE #Q1 #FY23 #Earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[9138,8667],"class_list":["post-133434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharma","tag-wellness"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":132753,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-ltd-q1fy23-profit-suffer-with-rise-in-expenses\/","url_meta":{"origin":133434,"position":0},"title":"Zydus Lifesciences Ltd Q1FY23; Profit suffer with rise in expenses","author":"Karan_Singh","date":"August 10, 2022","format":false,"excerpt":"Revenue for Q1 FY23 has increased by 1.8% YoY to \u20b940,727 millions. Profits decreased by 12% YoY to \u20b95,183 millions because Total Expenditure grew by 7% YoY for Q1 FY 2023. In this quarter\u2019s\u00a0results, it is clearly visible that the pharmacy business has been affected by the US price erosions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131835,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133434,"position":1},"title":"Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 1, 2022","format":false,"excerpt":"Key highlights from Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Management Update: SUNPHARMA recorded the highest ever quarterly revenue in 1Q23, with sales increasing 14% YonY, excluding the contribution of 1Q22. SUNPHARMA\u2019s current generic pipeline for the US includes 89 ANDAs and 13 NDAs awaiting approval with the\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":170087,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-q1-fy26-earnings-results\/","url_meta":{"origin":133434,"position":2},"title":"Zydus Lifesciences Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 12, 2025","format":false,"excerpt":"In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Zydus Lifesciences Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172227,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-q2-fy26-earnings-results\/","url_meta":{"origin":133434,"position":3},"title":"Zydus LifeSciences Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 7, 2025","format":false,"excerpt":"In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Zydus LifeSciences Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":158629,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-ltd-q3-fy24-earnings-conference-call-insights\/","url_meta":{"origin":133434,"position":4},"title":"Zydus Lifesciences Ltd Q3 FY24 Earnings Conference Call Insights","author":"Praveen","date":"February 12, 2024","format":false,"excerpt":"Key highlights from Zydus Lifesciences Ltd (ZYDUSLIFE) Q3 FY24 Earnings Concall India Formulations Double-digit growth led by volume expansion and new launches. Volume growth and new product launches drove growth. Gained market share in key therapies; chronic portfolio grew faster than market. Margin expansion from better product mix and operating\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":168476,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-ltd-q4fy25-0-fall-in-profits\/","url_meta":{"origin":133434,"position":5},"title":"Zydus Lifesciences Ltd Q4FY25; 0% fall in Profits","author":"Chirag Gupta","date":"May 21, 2025","format":false,"excerpt":"In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/3-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/3-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/3-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/3-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/3-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/3-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=133434"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133434\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=133434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=133434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=133434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}